[{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Reparixin","moa":"IL-8 receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Injection","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2022","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen-beta-receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"Dompe Farmaceutici","sponsor":"Inapplicable","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Other Small Molecule","year":"2020","type":"Inapplicable","leadProduct":"Raloxifene Hydrochloride","moa":"Estrogen-beta-receptor","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"Dompe Farmaceutici","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Oral","sponsorNew":"Dompe Farmaceutici \/ Inapplicable","highestDevelopmentStatusID":"8","companyTruncated":"Dompe Farmaceutici \/ Inapplicable"},{"orgOrder":0,"company":"ReiThera","sponsor":"BARDA","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"ITALY","productType":"Vaccine","year":"2020","type":"Funding","leadProduct":"ChAd3-SUDV","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase II","graph3":"ReiThera","amount2":0,"highestDevelopmentShortName":"Ph II","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Undisclosed","sponsorNew":"ReiThera \/ BARDA","highestDevelopmentStatusID":"8","companyTruncated":"ReiThera \/ BARDA"}]

Find Clinical Drug Development Pipelines & Deals | PipelineProspector

Xls
Filters Filter
×
FILTER:
filter
Company Name
    filter

    Year

      filter

      DEALS // DEV.

        filter

        Country

          filter
          Sponsor
            filter

            Therapeutic Area

              filter

              Study Phase

                filter

                Deal Type

                  filter

                  Product Type

                    filter

                    Dosage Form

                      filter

                      Lead Product

                        filter

                        Target

                          Loading...

                          Therapeutic Area by Lead Product

                          Study Phase by Lead Product

                          Company by Lead Product

                          Top Deals by Deal Size (USD bn)

                          01

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : Two papers, published in The Lancet and Nature, indicate that treatment with oral raloxifene, a selective estrogen receptor modulator (SERM) with a proven safety profile, may be efficacious against SARS-CoV-2 clinically relevant variants.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          July 26, 2022

                          Lead Product(s) : Raloxifene Hydrochloride

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank

                          02

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : This new funding from BARDA will enable Sabin and ReiThera to advance the investigational Ebola Sudan and Marburg vaccines through GMP manufacturing and release of ChAd3-MARV and ChAd3-SUDV Phase 2 clinical trial.

                          Product Name : ChAd3-SUDV

                          Product Type : Vaccine

                          Upfront Cash : Undisclosed

                          May 13, 2020

                          Lead Product(s) : ChAd3-SUDV

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : BARDA

                          Deal Size : $215.5 million

                          Deal Type : Funding

                          blank

                          03

                          Pharmex
                          Not Confirmed
                          Pharmex
                          Not Confirmed

                          Details : The REPAVID-19 clinical trial will evaluate efficacy and safety of Dompé’s Reparixin in hospitalized adult patients with severe COVID-19 pneumonia.

                          Product Name : Undisclosed

                          Product Type : Other Small Molecule

                          Upfront Cash : Inapplicable

                          January 09, 2020

                          Lead Product(s) : Reparixin

                          Therapeutic Area : Infections and Infectious Diseases

                          Highest Development Status : Phase II

                          Sponsor : Inapplicable

                          Deal Size : Inapplicable

                          Deal Type : Inapplicable

                          blank